Reuter U, et al. Long-term efficacy and safety of erenumab: Results from 64 weeks of the LIBERTY study. IHC-OR-006. IHC 2019 5-8 sept. Dublin, Ierland.
CVST-VITT in lage-, midden- en hoge-inkomenslanden
sep 2023 | Neuro-vasculair, Vaccinatie, Virale infecties